DAFNA Capital Management LLC Has $12.58 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

DAFNA Capital Management LLC cut its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 402,667 shares of the biopharmaceutical company’s stock after selling 3,868 shares during the quarter. Xenon Pharmaceuticals comprises approximately 3.2% of DAFNA Capital Management LLC’s holdings, making the stock its 5th largest holding. DAFNA Capital Management LLC’s holdings in Xenon Pharmaceuticals were worth $12,579,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Captrust Financial Advisors bought a new stake in shares of Xenon Pharmaceuticals during the third quarter worth $46,000. Macquarie Group Ltd. lifted its position in shares of Xenon Pharmaceuticals by 551.9% during the third quarter. Macquarie Group Ltd. now owns 3,514 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 2,975 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Xenon Pharmaceuticals by 104.1% during the fourth quarter. JPMorgan Chase & Co. now owns 4,775 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 119,961 shares during the period. Morgan Stanley increased its stake in shares of Xenon Pharmaceuticals by 101.7% during the first quarter. Morgan Stanley now owns 4,959 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 2,500 shares during the period. Finally, ProShare Advisors LLC purchased a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at $227,000.

XENE has been the topic of several research reports. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. StockNews.com upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. TheStreet upgraded Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Monday, March 14th. Wedbush reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. Finally, Zacks Investment Research lowered Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $41.80.

Shares of NASDAQ XENE traded up $0.11 during midday trading on Friday, reaching $26.65. The company had a trading volume of 12,158 shares, compared to its average volume of 459,889. The business’s 50-day simple moving average is $30.63 and its 200 day simple moving average is $29.86. The stock has a market cap of $1.42 billion, a P/E ratio of -14.83 and a beta of 1.75. Xenon Pharmaceuticals Inc. has a 1 year low of $14.65 and a 1 year high of $36.42.

Xenon Pharmaceuticals (NASDAQ:XENEGet Rating) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative net margin of 360.80% and a negative return on equity of 20.94%. During the same quarter in the previous year, the firm earned ($0.42) earnings per share. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -2.04 EPS for the current year.

In related news, Director Simon N. Pimstone sold 31,086 shares of the firm’s stock in a transaction on Monday, March 7th. The shares were sold at an average price of $30.50, for a total transaction of $948,123.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James R. Empfield sold 32,853 shares of the firm’s stock in a transaction on Monday, March 7th. The stock was sold at an average price of $30.54, for a total transaction of $1,003,330.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,974 shares of company stock valued at $2,899,047. 7.48% of the stock is currently owned by corporate insiders.

About Xenon Pharmaceuticals (Get Rating)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Featured Articles

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.